Phase I dose-escalation study of the thioxanthone SR271425 administered intravenously once every 3 weeks in patients with advanced malignancies

Investigational New Drugs ◽

10.1007/s10637-008-9135-2 ◽

2008 ◽

Vol 26 (4) ◽

pp. 347-354 ◽

Author(s):

Priscila H. Goncalves ◽

Francine High ◽

Paul Juniewicz ◽

Gareth Shackleton ◽

Jing Li ◽

...

Keyword(s):

Phase I ◽

Dose Escalation ◽

Dose Escalation Study ◽

Advanced Malignancies

Download Full-text

427 POSTER Pharmacokinetics (PK) of EZN-2208, a novel anticancer agent, in patients (pts) with advanced malignancies: a phase I dose-escalation study

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(08)72361-9 ◽

2008 ◽

Vol 6 (12) ◽

pp. 134 ◽

Author(s):

A. Patnaik ◽

M. Goldston ◽

C. Takimoto ◽

A. Tolcher ◽

K. Papadopoulos ◽

...

Keyword(s):

Phase I ◽

Dose Escalation ◽

Anticancer Agent ◽

Dose Escalation Study ◽

Advanced Malignancies

Download Full-text

A phase I dose-escalation study of XL147 (SAR245408), a PI3K inhibitor administered orally to patients (pts) with advanced malignancies.

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.3004 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. 3004-3004 ◽

Author(s):

G. Edelman ◽

C. Bedell ◽

G. Shapiro ◽

S. S. Pandya ◽

E. L. Kwak ◽

...

Keyword(s):

Phase I ◽

Dose Escalation ◽

Pi3k Inhibitor ◽

Dose Escalation Study ◽

Advanced Malignancies

Download Full-text

Phase I dose escalation study of pegylated liposomal doxorubicin (Caelyx®) in combination with topotecan in patients with advanced malignancies

Investigational New Drugs ◽

10.1007/s10637-006-7520-2 ◽

2006 ◽

Vol 24 (5) ◽

pp. 413-421 ◽

Author(s):

Hervé Ghesquières ◽

Sandrine Faivre ◽

Latifa Djafari ◽

Patricia Pautier ◽

Catherine Lhommé ◽

...

Keyword(s):

Phase I ◽

Dose Escalation ◽

Liposomal Doxorubicin ◽

Pegylated Liposomal Doxorubicin ◽

Dose Escalation Study ◽

Advanced Malignancies

Download Full-text

Phase I, multicenter, dose‐escalation study of avadomide in adult Japanese patients with advanced malignancies

Cancer Science ◽

10.1111/cas.14704 ◽

2020 ◽

Vol 112 (1) ◽

pp. 331-338

Author(s):

Kiyohiko Hatake ◽

Takaaki Chou ◽

Toshihiko Doi ◽

Yasuhito Terui ◽

Harumi Kato ◽

...

Keyword(s):

Phase I ◽

Dose Escalation ◽

Japanese Patients ◽

Dose Escalation Study ◽

Advanced Malignancies

Download Full-text

Clinical pharmacokinetics (PK) of EZN-2208, a novel anticancer agent, in patients (pts) with advanced malignancies: A phase I, first-in-human, dose-escalation study

Journal of Clinical Oncology ◽

10.1200/jco.2008.26.15_suppl.2556 ◽

2008 ◽

Vol 26 (15_suppl) ◽

pp. 2556-2556 ◽

Author(s):

Z. Guo ◽

J. J. Wheler ◽

A. Naing ◽

S. Mani ◽

S. Goel ◽

...

Keyword(s):

Phase I ◽

Dose Escalation ◽

Anticancer Agent ◽

Dose Escalation Study ◽

Clinical Pharmacokinetics ◽

Advanced Malignancies

Download Full-text

A phase I dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics of XL765 (SAR245409), a PI3K/TORC1/TORC2 inhibitor administered orally to patients (pts) with advanced malignancies.

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.3030 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. 3030-3030 ◽

Author(s):

I. Brana ◽

P. LoRusso ◽

J. Baselga ◽

E. I. Heath ◽

A. Patnaik ◽

...

Keyword(s):

Phase I ◽

Dose Escalation ◽

Dose Escalation Study ◽

Advanced Malignancies

Download Full-text

A phase I dose-escalation study of LY2875358, a bivalent MET antibody, given as monotherapy or in combination with erlotinib or gefitinib in Japanese patients with advanced malignancies

Investigational New Drugs ◽

10.1007/s10637-016-0370-7 ◽

2016 ◽

Vol 34 (5) ◽

pp. 584-595 ◽

Author(s):

Kiyotaka Yoh ◽

Toshihiko Doi ◽

Hironobu Ohmatsu ◽

Takashi Kojima ◽

Hideaki Takahashi ◽

...

Keyword(s):

Phase I ◽

Dose Escalation ◽

Japanese Patients ◽

Dose Escalation Study ◽

Advanced Malignancies

Download Full-text

Abstract B51: A phase I dose‐escalation study of MGCD265 in patients with advanced malignancies (study 265‐102)

10.1158/1535-7163.targ-09-b51 ◽

2009 ◽

Author(s):

Patricia LoRusso ◽

Razelle Kurzrock ◽

Amy Weise ◽

Elisabeth Heath ◽

Michel Drouin ◽

...

Keyword(s):

Phase I ◽

Dose Escalation ◽

Dose Escalation Study ◽

Advanced Malignancies

Download Full-text

405 POSTER A phase I dose-escalation study of the safety and pharmacokinetics of a XL184, a VEGFR and Met kinase inhibitor, administered orally to subjects with advanced malignancies

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(06)70410-4 ◽

2006 ◽

Vol 4 (12) ◽

pp. 124-125 ◽

Author(s):

R. Kurzrock ◽

L. Camacho ◽

D. Hong ◽

C. Ng ◽

L. Janisch ◽

...

Keyword(s):

Phase I ◽

Dose Escalation ◽

Kinase Inhibitor ◽

Dose Escalation Study ◽

Advanced Malignancies

Download Full-text

Abstract CT-02: A phase I, open label, dose escalation study of oral mammalian target of rapamycin inhibitor INK128 administered by intermittent dosing regimens in patients with advanced malignancies

10.1158/1538-7445.am2012-ct-02 ◽

2012 ◽

Author(s):

Josep Tabernero ◽

Andres Cervantes ◽

Michael S. Gordon ◽

Elena G. Chiorean ◽

Howard A. Burris ◽

...

Keyword(s):

Phase I ◽

Dose Escalation ◽

Mammalian Target Of Rapamycin ◽

Target Of Rapamycin ◽

Dose Escalation Study ◽

Advanced Malignancies ◽

Dosing Regimens

Download Full-text